Abstract: Method for suppressing bone cancer-induced allodynia in a patient, the method comprising administration of a therapeutically effective amount of a non-cytotoxic protease to a patient suffering from bone cancer.

Abstract: The present disclosure provides modules, instruments and methods to enrich for cells edited via nucleic acid-guided nuclease editing of live cells.

Abstract: The present invention relates to sensors and methods for detecting bacterial proteases in a sample. In particular, the present invention relates to sensors and methods for detecting Pseudomonas spp. protease activity in a sample. The sensors and methods may be used to detect or predict spoilage of a dairy product. The invention also relates to methods for preparing samples for protease assays.

Abstract: Allografts for soft tissue repair, including breast reconstruction and other plastic surgery procedures, are disclosed. One allograft is made from decellularized dermal tissue and constitutes a collagen matrix having substantially uniform density and porosity. Another allograft is a hybrid bilayer tissue form that is made from decellularized dermal and adipose tissues. Methods for making both allografts are also disclosed.

Abstract: The present invention relates to compositions comprising a polymeric matrix or a gel containing functional enzymes capable of re-creating under culture conditions the cell microenvironment existing in vivo. The present invention also relates to devices for cell cultures comprising such compositions, in particular hydrogel and the use thereof to control the chemical microenvironment of a cell culture or mimic physiological or pathological conditions of the in vivo cells. The compositions and the devices described herein could be also used in vitro for evaluating the therapeutic effect of a compound on a determined cell line or on primary cells.

Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

Abstract: Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.

Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.

Abstract: To provide a means capable of obtaining further excellent cellular adhesiveness than in a case where a surface of a cell culture substrate (cell culture vessel) is coated using polytetrahydrofurfuryl acrylate (PTHFA). Provided is a cell culture substrate comprising a coating layer on at least one side of a polymer substrate, wherein the coating layer includes a copolymer comprising more than 20% by mole and less than 100% by mole of a structural unit (1) derived from furfuryl (meth)acrylate represented by Formula (1) and more than 0% by mole and less than 80% by mole of a structural unit (2) derived from ethylenically unsaturated monomer having a hydroxyl group (the total of the structural unit (1) and the structural unit (2) is 100% by mole).

Abstract: The present invention relates to rusalatide acetate compositions, formulations and dosage forms that include 23 amino acid monomer (“Monomer”), dimer (“Dimer”) of two 23 amino acid Monomers, or any combination of Monomer and Dimer, wherein any ratio, proportion or percentage of Monomer and Dimer may be present in the compositions, formulations and dosage forms. The invention also broadly covers stable compositions, formulations or dosage forms that include rusalatide acetate and any pharmaceutically acceptable salts thereof.

Abstract: Provided herein are compositions and method for producing ?-polyglutamic acid (PGA). In particular, provided herein are bacterial co-culture systems and methods for producing PGA.

Abstract: The present application relates to a lyophilized scaffold composition having at least one polysaccharide wherein said scaffold is substantially solid and capable of being formed into a desired shape; wherein the at least one polysaccharide has a protonation level resulting in controlled rehydration of said scaffold, such that when said scaffold is contacted with at least one of a neutral aqueous solution, blood, blood derived fluid and combinations thereof, said scaffold forms a microparticle dispersion and stimulates tissue remodeling and anabolic wound repair, a process for preparing a lyophilized scaffold composition and the use of a lyophilized scaffold composition for wound repair in a mammal.

Abstract: Provided is a means for identifying cells suitable for transplantation into a cornea, or a means for producing a cell population suitable for transplantation into a cornea using the same. A method for producing a cell population suitable for transplantation into a cornea, the method comprising the steps of (1) preparing a cell population cultured under conditions suitable for inducing differentiation into corneal endothelial cells, and (2) measuring the expression of at least one gene selected from the group consisting of POU6F2, LMX1B, and TFAP2B in the cell population.

Abstract: A method for collecting a fine particle stored in a structure by suctioning the fine particle using a nozzle, in which, as the structure, a structure in which at least one communication portion that communicates a space storing the fine particle with one surface side and the other surface side of the structure is formed is used.

Abstract: A product named functional food, and in one of its presentations, it consists of a powder made up with coffee and/or cocoa by-products which are myceliated with macromycete or entomopathogenic macromycete. The latter are produced, mixed and enriched with nutrients from its own cultivation substrate. The result is an innovative product that is rich in protein, polysaccharides, antioxidants and low in caffeine. The functional food obtained has an increase of 15% to 20% in protein with respect to the initial byproduct and a notable increase in the amount of antioxidants This is attributed to the initial substrate and the activity of the mushrooms that are cultivated in it.

Abstract: A process is provided for forming a fuel or a fuel intermediate from two fermentations that includes feeding an aqueous solution comprising a fermentation product from a first bioreactor to a second bioreactor and/or a stage upstream of the second bioreactor, which also produces the fermentation product. The aqueous solution may be added at any stage of the second fermentation and/or processing steps upstream from the second bioreactor that would otherwise require the addition of water. Accordingly, the product yield is increased while fresh/treated water usage is decreased.

Abstract: An in vitro population of human brain endothelial cells (hBECs) expressing claudin-5, occludin, ZO-1 and GLUT-1 and expressing one or more of FZD7, WNT7A, WNT7B, APCDD1, STRA6 and ZO-3 is provided. A blood brain barrier (BBB) comprising the hBECs and use of the BBB for analyzing permeability characteristics of a test agent are provided.

Abstract: Isolating or identifying a cell based on a physical property of said cell can include providing a cell suspension; passing said suspension through a microfluidic channel that includes a constriction; passing the cell suspension through the constriction; and, contacting said cell suspension solution with a compound. The constriction can be sized to preferentially deform a relatively larger cell compared to a relatively smaller cell.

Abstract: A sectionable tissue sample support structure including a gel compound formed into a self supporting geometric shape for retention and orientation of at least one tissue sample during a histopathology process including processing, embedding and microtome slicing of the tissue sample. A method of orienting, processing, embedding and microtome slicing a tissue sample using a gel compound preformed into a self supporting geometric shape. A combination including the sectionable tissue sample support structure and a package containing the sectionable tissue sample support structure.

Abstract: This disclosure provides systems and methods for seeding cell cultures in a microfluidic device. The systems and methods of this disclosure can enable flow of a cell solution from one side of a scaffold, such as a porous substrate or membrane, to the other side of the scaffold. Flow of the liquid can pass through the scaffold while the cells themselves do not, resulting in the cells driven to the surface of the scaffold for consequent attachment. A microfluidic device can include a microfluidic feature structured to create a seal between a cell seeding tool and an inlet to a microchannel of the microfluidic device. This can enable a pressure-driven flow to push fluid down the channel and through pores of the membrane. In contrast, traditional gravity fed seeding of cells may not create enough pressure to drive fluid through the pores of the scaffold.